Trial Profile
An open label, cross-over, drug interaction study of Entospletinib alone, or with cobicistat,rifampin, fluconazole, rosuvastatin or digoxin in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Apr 2016
Price :
$35
*
At a glance
- Drugs Cobicistat (Primary) ; Digoxin (Primary) ; Entospletinib (Primary) ; Fluconazole (Primary) ; Rifampicin (Primary) ; Rosuvastatin (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 21 Apr 2016 New trial record
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics